Viruses, friends, and foes: The case of Torque Teno Virus and the net state of immunosuppression

• Published in: Transplant infectious disease Vol. 24; no. 2; pp. e13778 - n/a
• Main Authors: Redondo, Natalia, Navarro, David, Aguado, José María, Fernández‐Ruiz, Mario
• Format: Journal Article
• Language: English
• Published: Denmark Wiley Subscription Services, Inc 01.04.2022
• Subjects: Antiviral agents; Antiviral drugs; Biomarkers; Clinical trials; Deoxyribonucleic acid; DNA; DNA, Viral; Friends; Graft rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hematopoietic stem cells; Humans; Immunology; Immunosuppression; Immunosuppression Therapy - adverse effects; Immunosuppressive agents; infection; Kinetics; Lymphocytes; Pathological effects; Polymerase chain reaction; Rejection; Risk assessment; solid organ transplantation; Standardization; Stem cell transplantation; Stem cells; Strategy; Torque; Torque Teno Virus (TTV); Torque teno virus - genetics; Transplantation; Transplants & implants; Viral Load; Viremia; Viruses; hematopoietic stem cell transplantation; immunosuppression; solid organ transplantation; infection; rejection; Torque Teno Virus (TTV)
• ISSN: 1398-2273; 1399-3062; 1399-3062
• DOI: 10.1111/tid.13778

New reliable biomarkers are needed to improve individual risk assessment for post‐transplant infection, acute graft rejection and other immune‐related complications after solid organ transplantation (SOT) and allogeneic hematopoietic stem cell transplantation (allo‐HSCT). One promising strategy relies on the monitoring of replication kinetics of virome components as functional surrogate for the net state of immunosuppression. Torque Teno Virus (TTV) is a small, non‐enveloped, circular, single‐stranded DNA anellovirus with no attributable pathological effects. A major component of the human blood virome, TTV exhibits various features that facilitate its application as immune biomarker: high prevalence rates, nearly ubiquitous distribution, stable viral loads with little intra‐individual variability, insensitivity to antiviral drugs, and availability of commercial PCR assays for DNA quantification. The present review summarizes the available studies supporting the use of post‐transplant TTV viremia to predict patient and graft outcomes after SOT and allo‐HSCT. Taken together, this evidence suggests that high or increasing TTV DNA levels precede the occurrence of infectious complications in the SOT setting, whereas low or decreasing viral loads are associated with the development of acute rejection. The interpretation in allo‐HSCT recipients is further complicated by complex interplay with the underlying disease, conditioning regimen, and timing of recovery of lymphocyte counts, although TTV kinetics may act as a marker of immunological reconstitution at the early post‐transplant period. The standardization of PCR methods and reporting units for TTV DNAemia and the results from ongoing interventional trials evaluating a TTV load‐guided strategy to adjust immunosuppressive therapy are achievements expected in the coming years.